Skip to main content
. 2016 Jun 9;18(6):387–397. doi: 10.1016/j.neo.2016.04.006

Figure 2.

Figure 2

Cellularity (A), percentages of mitotic cells (B), caspase-3–activated area (C), and percentages of Ki-67–positive cells (D) for Nab-paclitaxel–/PBS-treated OVCAR-8 and NCI/ADR-RES tumors. *P < .05 as measured by one-way ANOVA with an FDR posttest.